Orin Green Financial’s Protalix BioTherapeutics PLX Stock Holding History

Orin Green Financial’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.3K	Sell	10,000 -54,433	-84%	-$115K	0.01%	82
2026 Q1	$140K	Buy	64,433 +3,000	+5%	+$7.45K	0.06%	75
2025 Q4	$111K	Buy	61,433 +233	+0.4%	+$476	0.04%	73
2025 Q3	$136K	Hold	61,200	–	–	0.05%	83
2025 Q2	$90.6K	Buy	61,200 +11,200	+22%	+$22.9K	0.04%	76
2025 Q1	$128K	Buy	+50,000	New	+$119K	0.06%	72
2024 Q4	–	Sell	-72,000	Closed	-$102K	–	75
2024 Q3	$73.4K	Hold	72,000	–	–	0.03%	80
2024 Q2	$84.2K	Buy	+72,000	New	+$85.1K	0.04%	74
2024 Q1	–	Sell	-80,000	Closed	-$119K	–	76
2023 Q4	$142K	Hold	80,000	–	–	0.07%	74
2023 Q3	$133K	Buy	80,000 +19,850	+33%	+$35.6K	0.07%	67
2023 Q2	$120K	Buy	+60,150	New	+$143K	0.06%	67

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Orin Green Financial's PLX Position: Q2 2026 in Review

Orin Green Financial reduced its Protalix BioTherapeutics (PLX) stake by 84% in Q2 2026, selling an estimated $115K and leaving 10,000 shares worth $23.3K. The position accounts for 0.01% of the portfolio, ranked #82.

Orin Green Financial first reported a position in PLX in Q2 2023 and has held it in 11 quarters since. The position peaked at $142K in Q4 2023. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Orin Green Financial held 10,000 shares of Protalix BioTherapeutics worth $23.3K as of Q2 2026.
Orin Green Financial sold 54,433 Protalix BioTherapeutics shares in Q2 2026, an estimated $115K.
Protalix BioTherapeutics made up 0.01% of Orin Green Financial's portfolio in Q2 2026, its #82 holding.
Orin Green Financial first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 11 quarters since.
Orin Green Financial's Protalix BioTherapeutics position peaked at $142K in Q4 2023.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Orin Green Financial's 13F filing for Q2 2026, filed 13 Jul 2026.